Anthony E. Dobranowski
BA, MBA, CPA, CA
Chair of the Compensation, Corporate Governance & Nominating Committee
Rob Harris has over 35 years of pharmaceutical industry experience in both Canada and the United States in sales, marketing, business development and general management.
Mr. Harris most recently served as President and CEO of Tribute Pharmaceuticals. Prior to co-founding Tribute Pharmaceuticals, Rob was the President & CEO of Legacy Pharmaceuticals Inc. Mr. Harris also has previous experience at Biovail Corporation where as VP of Business Development he was involved, led and successfully concluded numerous business development transactions, including the licensing of new chemical entities, the acquisition of mature products, the completion of co-promotion deals, distribution agreements, product development and reformulation transactions. Mr. Harris joined Biovail in 1997 as the GM of Biovail Pharmaceuticals Canada at a time when the company experienced rapid growth in the Canadian division.
Before Biovail, Mr. Harris worked in various senior commercial management positions during his twenty-year tenure at Wyeth (Ayerst) including its consumer products and animal health groups and has been involved in numerous product launches during his career. Mr. Harris is also a past member of the Board of Directors of Tribute Pharmaceuticals, Aralez Pharmaceuticals Inc. and CannaRoyalty Corp. d/b/a Origin House.
Mr. London has over 30 years of experience managing and advising a wide variety of public and private businesses. From 2005 to 2018 Mr. London held senior executive positions with Nuvo Pharmaceuticals and its predecessor Nuvo Research, including Vice Chairman (2005-2009), President and Co-CEO (2009-2016), President and CEO (2016-2017) and Executive Chairman (2018). In January of 2019, he assumed his current role as non-executive Vice Chairman of the Board of Directors.
Mr. London is currently the Chair of the Strategic Advisory Board and Executive in Residence at the John F. Wood Centre for Business and Student Enterprise at the Gordon S. Lang School of Business and Economics at the University of Guelph and is an Advisory Board Member of the Masters of Biomedical Discovery and Commercialization program at McMaster University. Mr. London is also a member for the board of directors of Crescita Therapeutics Inc.
From 2002 to 2005, Mr. London was President and Chief Executive Officer of Powercart Systems Inc., a Canadian-based private company that designs and manufactures battery-equipped workstations that power devices with wireless communication capability. In 1997, Mr. London co-founded Nighthawk Investments, a private venture capital investment firm. In 1994, Mr. London co-founded Triam Automotive Inc., an international automotive parts manufacturer, where he served as Executive Vice-President. Triam completed its initial public offering in 1994 and was sold to Magna International Inc. in 1998. From 1988 to 1993, he was Executive Vice-President, Secretary and General Counsel at Atoma International, Magna’s interior systems group. Prior to joining Magna, Mr. London was a partner with the Toronto law firm of Strathy, Archibald and Seagram (now Gowlings) where from 1981 to 1988 he practiced corporate law with a focus on banking and insolvency.
Mr. London is a graduate of the University of Western Ontario law school and holds a Masters of Law Degree from University College London.
Mr. Chicoine is currently the Executive Chairman of the Board of Crescita Therapeutics Inc. and Chairman of the Audit Committee and a Director on the Board of NeuPath Health Inc. Previously, Mr. Chicoine served as Nuvo’s Chairman and Co-CEO and was actively involved in its day-to-day operations since 2004. From 2001-2004, Mr. Chicoine served as the Chief Financial Officer at Cosma International, Magna’s body and chassis systems group. Mr. Chicoine served as the President of PowerCart Systems Inc., a Markham-based private company that designs and manufactures battery-equipped workstations that power devices with wireless communication capability.
Previously, he served as Vice Chairman in charge of sales at Triam Automotive Inc. From 1982 to 1993, Mr. Chicoine held various positions at the Magna group of companies, including President and CEO of Atoma International Inc. While Mr. Chicoine was the CEO of Atoma, he succeeded in growing its business from $300 million per annum to $1 billion and effected a major restructuring.
Mr. Chicoine is a graduate of the University of Toronto in commerce and is a Chartered Professional Accountant.
Private Business Investor. Mr. Copeland was the former President and Chief Operating Officer, Triam Automotive Inc., an automobile parts supplier. Prior to Triam, Mr. Copeland was Chief Financial Officer of Magna International Inc. and Chief Executive Officer of the Cosma Group of Magna. Mr. Copeland has been an advisor, investor and director in a number of private early stage companies since 1998. He is a Chartered Professional Accountant whose background includes a focus on business valuation and mergers and acquisitions.
Private Business Investor. Mr. Dobranowski retired from Magna International Inc., a global automotive parts supplier, in 2007. During his employment with Magna, Mr. Dobranowski was most recently a Vice President of Magna, and prior to that held various executive positions (Vice Chairman, President and CFO) at Tesma International Inc., a publicly traded Magna subsidiary. He was instrumental in the initial public offering of Tesma in 1995, and was involved in all aspects of Tesma’s growth, with particular emphasis on financing, investor relations and M&A activity. Previous to that, Mr. Dobranowski held various senior management positions with other Magna companies. Mr. Dobranowski holds an MBA from the University of Toronto and is also a Chartered Professional Accountant.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
